Table 2.
Disease/clinical parameters and PROs over time
| Baseline N = 102 |
Month 4 N = 93 |
Month 8 N = 71 |
Month 12 N = 56 |
|
|---|---|---|---|---|
| Disease/clinical parameters | ||||
| cDAPSA score, mean (SD) | 22.3 (13.2) | 13.3 (11.0) | 11.1 (9.0) | 12.6 (9.9) |
| SJC (0–66), mean (SD) | 5.4 (5.4) | 2.8 (1.5) | 2.8 (1.3) | 2.8 (1.0) |
| TJC (0–68), mean (SD) | 7.5 (6.7) | 4.3 (6.5) | 2.7 (3.3) | 3.2 (5.6) |
| PtGA VAS (0–100 mm), mean (SD) | 50.2 (24.6) | 38.3 (25.7) | 38.3 (26.9) | 44.1 (28.6) |
| Pain VAS (0–100 mm), mean (SD) | 48.6 (25.4) | 37.7 (24.9) | 35.9 (25.7) | 38.1 (25.5) |
| PhGA VAS (0–100 mm), mean (SD) | 43.1 (19.1) | 24.6 (17.5) | 21.6 (18.0) | 18.8 (16.0) |
| Enthesitis, n/m (%) | 33/97 (34.0) | 21/86 (24.4) | 10/55 (18.2) | 9/48 (18.8) |
| Resolution of enthesitisa, n/m (%) | – | 15/27 (55.6) | 12/17 (70.6) | 6/10 (60.0) |
| Dactylitis, n/m (%) | 18/99 (18.2) | 10/86 (11.6) | 5/63 (7.9) | 1/51 (2.0) |
| Resolution of dactylitisb, n/m (%) | – | 7/17 (41.2) | 10/15 (66.7) | 9/9 (100.0) |
| BSA (%), mean (SD) | 3.0 (6.0) | 1.4 (3.0) | 1.1 (2.5) | 0.9 (1.8) |
| PROs | ||||
| HAQ-DI (0–3), mean (SD) | 0.9 (0.7) | 0.7 (0.7) | 0.7 (0.6) | 0.6 (0.6) |
| SF-36v2, mean (SD) | ||||
| PCS score | 34.4 (11.1) | 37.5 (11.2) | 38.1 (10.2) | 39.0 (10.7) |
| MCS score | 45.5 (11.7) | 49.0 (11.7) | 50.8 (10.0) | 49.6 (10.5) |
The number of patients with data available for each parameter may vary
N the number of patients in the study at the time point, n/m the number of patients with the condition/the number of patients with data available for the assessment
BSA psoriasis-involved body surface area, cDAPSA Clinical Disease Activity Index for PsA, HAQ-DI Health Assessment Questionnaire-Disability Index, MCS mental component score, PCS physical component score, PhGA Physician’s Global Assessment of PsA, PROs patient-reported outcomes, PtGA Patient’s Global Assessment of PsA, SD standard deviation, SF-36v2 36-item Short Form Health Survey version 2.0, SJC swollen joint count, TJC tender joint count, VAS visual analog scale
aPercentages based on patients with enthesitis at baseline (N = 33) and available enthesitis data during follow-up
bPercentages based on patients with dactylitis at baseline (N = 18) and available dactylitis data during follow-up